Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine

Hum Vaccin Immunother. 2021 Nov 2;17(11):4093-4096. doi: 10.1080/21645515.2021.1954826. Epub 2021 Aug 4.

Abstract

Guillain-Barre syndrome (GBS) is an acute immune-mediated disease of the peripheral nerves and nerve roots (polyradiculoneuropathy) that is usually elicited by various infections. We present a case of GBS after receiving the second dose of Pfizer-COVID 19 vaccine. Diagnosis was made after performing an accurate clinical examination, electromyoneurography and laboratory tests. In particular, anti-ganglioside antibodies have tested positive. During this pandemic with ongoing worldwide mass vaccination campaign, it is critically important for clinicians to rapidly recognize neurological complications or other side effects associated with COVID-19 vaccination.

Keywords: Pfizer-BioNTech COVID-19 vaccine; anti-ganglioside antibodies; electromyoneurography; guillain-barre syndrome; neurological complications.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Guillain-Barre Syndrome* / chemically induced
  • Guillain-Barre Syndrome* / diagnosis
  • Humans
  • Laboratories
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines

Grant support

This paper did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.